NewAmsterdam Pharma Company N.V. (NAMS)

NASDAQ: NAMS · IEX Real-Time Price · USD

21.21

-0.59 (-2.69%)

Apr 25, 2024, 10:30 AM EDT - Market open

NAMS Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020
Cash & Equivalents	340.45	467.73	53.09	1.37
Cash & Cash Equivalents	340.45	467.73	53.09	1.37
Cash Growth	-27.21%	780.98%	3789.26%	-
Receivables	6.34	10.25	5.78	0
Other Current Assets	0	0	0	0.5
Total Current Assets	346.79	477.98	58.87	1.87
Property, Plant & Equipment	0.1	0.15	0.19	0
Long-Term Investments	0	0	0.72	138
Goodwill and Intangibles	0.17	0.21	0	0
Other Long-Term Assets	0.04	0.16	0	0
Total Long-Term Assets	0.31	0.52	0.91	138
Total Assets	347.1	478.5	59.78	139.87
Accounts Payable	16.92	11.85	9.83	0.16
Deferred Revenue	9.96	18.67	0	0
Current Debt	0.06	0.07	0.05	0
Other Current Liabilities	22.95	5.47	0	0.07
Total Current Liabilities	49.9	36.06	9.88	0.24
Long-Term Debt	0	0.06	0.11	0
Other Long-Term Liabilities	8.81	12.31	0	12.17
Total Long-Term Liabilities	8.81	12.37	0.11	12.17
Total Liabilities	58.7	48.43	9.99	12.41
Total Debt	0.06	0.13	0.16	0
Debt Growth	-52.38%	-23.17%	-	-
Retained Earnings	-316.97	-140.04	-34.68	-10.54
Comprehensive Income	4.42	4.42	0	0
Shareholders' Equity	288.39	430.07	49.79	-10.54
Net Cash / Debt	340.39	467.6	52.93	1.37
Net Cash / Debt Growth	-27.21%	783.47%	3777.24%	-
Net Cash Per Share	-	-	2.98	0.20
Working Capital	296.89	441.92	48.99	1.63
Book Value Per Share	2.96	5.54	2.81	-1.60

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).